Milad Rouhimoghadam MSc, PhD

Milad Rouhimoghadam, MSc, Ph.D., is a Senior Scientist at AbbVie. Prior to joining AbbVie, Milad was focused on a targeted protein degradation platform and the discovery of novel therapeutic strategies for cancer. At AbbVie, Milad is leading the NanoBRET Platform within the Targeted Protein Degradation group, where he is developing cell-based NanoBRET assays to support the discovery of novel degraders, E3 ligases, and molecular glues, enabling high-throughput MOA profiling and mechanistic insights across programs.